RAVENQUEST BIOMED ORD SHS EBIT

RAVENQUEST BIOMED ORD SHS (RVVQF) currently reports a EBIT of $-30M as of July 2019. That compares with $-9.2M in the prior-year period — down 223.9% year over year. That is below the sector sector average of $2.5T. Use the charts on this page to explore RAVENQUEST BIOMED ORD SHS's EBIT history and peer comparisons.

RAVENQUEST BIOMED ORD SHS's EBIT decreased from $-9.2M to $-30M — a 223.9% year-over-year decrease (period ending July 2019). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

RAVENQUEST BIOMED ORD SHS's EBIT of $-30M is lower than the its sector sector average of $2.5T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

RAVENQUEST BIOMED ORD SHS reported $-30M in EBIT as of July 2019. That compares with $-9.2M in the prior-year period — down 223.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-30M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.5T. From there, open related valuation or income-statement pages for RAVENQUEST BIOMED ORD SHS, and consider following RVVQF for alerts when major investors trade the stock.